Loading stock…

Ionis Pharmaceuticals, Inc. (IONS) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Ionis Pharmaceuticals, Inc.

IONSMarket cap $7.34BPrice $44.2

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops RNA-targeted drugs that silence disease-causing genes before they make harmful proteins. Ionis pioneered this antisense technology decades before mRNA became a household word, and its treatments already help patients with rare genetic diseases no other drugs could touch.

In Bastion Portfolios?

52W Return-40%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+17%9

Revenue Forecast

Rev CAGR (1y)-5%1

Rev CAGR (3y)+24%9

Rev CAGR (5y)+27%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+30%5

Quality

Margins

EBIT Margin-68%1

Net Income Margin-65%1

Free Cash Flow Margin-64%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-105%1

ROA-19%1

Earnings Stabilityna–

GEAR+VERY WEAK6

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)282

P/BV16.71

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-7.6%1

Dividend Yieldna–

Momentum

Short term

1 month return-22%1

3 month return-48%1

YTD return-44%1

Mid term

Price vs 52wHigh51%1

1 year return-37%1

Long term

3 year return-5%3

5 year return+30%5

Risk Shield

Price Risk

Beta0.94

Volatility44%4

Free Cash Flow

Free Cash Flow Margin-64%1

Free Cash Flow Yield-7.6%1

Quality

ROCE-25%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

IONSIonis Pharmaceuticals

Revenue FY25$944M

GROWTH RATING↗

STRONG69 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+17%9

Revenue, next 1Y-5%1

Revenue, next 3Y, CAGR+24%9

Revenue, next 5Y, CAGR+27%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 69% of companies worldwide.

Revenue grew 17%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 24%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 17%/yr over the last 3 years and is set to grow 24%/yr from here.

The runway holds up: revenue is set to grow 27%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK4 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-22%1

3-month return-48%1

YTD return-44%1

MID & LONG-TERM▾SCORE

% of 52-week high51%1

1-year return-37%1

3-year return-5%3

5-year return+30%5

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (-4.8% over three years and +30% over five), roughly average for the market.

WEAKNESSES

It's down 37% over the past year, now 49% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-22%), over three months (-48%) and so far this year (-44%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Ionis Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

IONSIonis Pharmaceuticals

Revenue FY25$944M

GROWTH RATING↗

STRONG69 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+17%9

Revenue, next 1Y-5%1

Revenue, next 3Y, CAGR+24%9

Revenue, next 5Y, CAGR+27%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 69% of companies worldwide.

Revenue grew 17%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 24%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 17%/yr over the last 3 years and is set to grow 24%/yr from here.

The runway holds up: revenue is set to grow 27%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK4 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-22%1

3-month return-48%1

YTD return-44%1

MID & LONG-TERM▾SCORE

% of 52-week high51%1

1-year return-37%1

3-year return-5%3

5-year return+30%5

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (-4.8% over three years and +30% over five), roughly average for the market.

WEAKNESSES

It's down 37% over the past year, now 49% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-22%), over three months (-48%) and so far this year (-44%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Ionis Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community